Holen Sie sich die Stockscreener-App
0.00
100.00%
-17.03
Handel nachbörslich:
17.04
17.04
+
Schlusskurs vom Vortag:
$17.03
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$884.18M
Einnahmen:
$109.78M
Nettoeinkommen (Verlust:
$114.54M
KGV:
0.00
EPS:
2.2046
Netto-Cashflow:
$268.74M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$17.08
52-Wochen-Spanne:
$0.00
$21.03
Theravance Biopharma Inc Stock (TBPH) Company Profile
Firmenname
Theravance Biopharma Inc
Sektor
Branche
Telefon
650-808-6000
Adresse
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Compare TBPH vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TBPH
Theravance Biopharma Inc
|
0.00 | 884.18M | 109.78M | 114.54M | 268.74M | 2.2046 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2026-03-04 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2025-12-03 | Eingeleitet | Oppenheimer | Outperform |
| 2025-09-12 | Eingeleitet | B. Riley Securities | Buy |
| 2024-08-06 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-04-12 | Eingeleitet | BTIG Research | Buy |
| 2024-01-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2021-11-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-09-15 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-08-25 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2021-08-24 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-10-14 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-07 | Eingeleitet | JP Morgan | Overweight |
| 2020-06-15 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-05-13 | Eingeleitet | Cowen | Outperform |
| 2020-01-08 | Bestätigt | H.C. Wainwright | Buy |
| 2019-11-06 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2019-10-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-29 | Fortgesetzt | Piper Jaffray | Overweight |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-06-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-05-11 | Bestätigt | Needham | Buy |
| 2016-12-21 | Eingeleitet | Needham | Buy |
| 2016-11-03 | Eingeleitet | Piper Jaffray | Overweight |
| 2016-10-12 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2016-08-03 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2016-06-20 | Eingeleitet | Guggenheim | Buy |
| 2016-06-20 | Bestätigt | Leerink Partners | Outperform |
| 2016-05-12 | Eingeleitet | Leerink Partners | Outperform |
| 2016-05-05 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2015-02-03 | Hochstufung | Robert W. Baird | Underperform → Neutral |
Alle ansehen
Theravance Biopharma Inc Aktie (TBPH) Neueste Nachrichten
Theravance Biopharma (TBPH) shares were canceled on September 23 after its Zymeworks merger. - Stock Titan
Theravance Biopharma Insider Brett Grimaud Reports Complete Share Cancellation Following Zymeworks Merger - Kalkine Media
Form 4 Theravance Biopharma For: 24 September By Investing.com - Investing.com Canada
Zymeworks now owns Theravance Biopharma (TBPH). A director's shares were canceled for cash and milestone rights. - Stock Titan
A director's shares became rights to $17 each plus a contingent payment in Theravance Biopharma's (TBPH) merger. - Stock Titan
A 150,000-share insider option was cancelled without payment in Theravance Biopharma (TBPH)'s merger. - Stock Titan
Vancouver biotech Zymeworks closes US$929M Theravance deal - biv.com
Zymeworks Completes Acquisition of Theravance Biopharma - Indovizka.com
TBPH Suspended by BTIGAnalyst Rating Remains Neutral - GuruFocus
Zymeworks Finalizes Merger with Theravance Biopharma and Launches $350M Senior Secured Notes - Kalkine Media
Precision Trading with Theravance Biopharma Inc. (TBPH) Risk Zones - Stock Traders Daily
Zymeworks completes acquisition of Theravance Biopharma By Investing.com - Investing.com Australia
Theravance Biopharma CEO Rick E Winningham resigns; Kristin Stafford, Scott Platshon and Paul Schneider named directors - TradingView
Theravance Biopharma (Nasdaq: TBPH) is named in a notice to remove its shares from Nasdaq. - Stock Titan
Zymeworks completes acquisition of Theravance Biopharma - Investing.com
Theravance Biopharma, Inc. Announces Resignation of Rick E Winningham from Chief Executive Officer, Effective September 23, 2026 - marketscreener.com
A $350 million debt issue helped fund Zymeworks (ZYME)'s Theravance acquisition, with cash due per eligible share. - Stock Titan
Theravance Biopharma, Inc.(NasdaqGM:TBPH) dropped from S&P Pharmaceuticals Select Industry Index - marketscreener.com
Theravance Biopharma, Inc.(NasdaqGM:TBPH) dropped from NASDAQ Biotechnology Index - marketscreener.com
Theravance Biopharma issues disclosures amid Zymeworks merger - TipRanks
Form 8K Theravance Biopharma Inc For: 18 September By Investing.com - Investing.com Nigeria
Theravance Biopharma Shareholders Endorse Merger with Zymeworks Inc. - Kalkine Media
Theravance Biopharma shareholders approve merger with Zymeworks - Investing.com
Theravance Biopharma shareholders approve merger with Zymeworks By Investing.com - Investing.com Nigeria
Theravance Biopharma SVP Farnum Rhonda Sells 13,314 Shares at $17.03 Each - Kalkine Media
Theravance Biopharma, Inc. (TBPH) Stock Analysis: Navigating the Biotech Seas with Strategic Collaborations - DirectorsTalk Interviews
Theravance Biopharma (TBPH) Insider Sale: SVP, COMM & MEDICAL AF - GuruFocus
Theravance Biopharma SVP Rhonda Farnum sells $226k in stock - Investing.com India
Theravance Biopharma SVP Rhonda Farnum sells $226k in stock By Investing.com - Investing.com South Africa
Pre-arranged stock sale at Theravance Biopharma (TBPH) - Stock Titan
Theravance Biopharma (NASDAQ: TBPH) officer plans $226,793 stock sale - Stock Titan
Price-Driven Insight from (TBPH) for Rule-Based Strategy - Stock Traders Daily
Theravance Biopharma Inc (NASDAQ: TBPH) Share Price, TBPH Stock News, TBPH Share Price & Updates - kalkine.com.au
Form 8K Theravance Biopharma Inc For: 10 September By Investing.com - Investing.com South Africa
Theravance Bi in merger with Zymeworks faces shareholder suits, supplements proxy with disclosures - TradingView
Theravance Bio (TBPH) Up 0.8% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Theravance Biopharma Inc. (TBPH) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Theravance Biopharma Inc. (TBPH) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
How (TBPH) Movements Inform Risk Allocation Models - Stock Traders Daily
Theravance Biopharma reports CYPRESS Phase 3 miss but FDA grants Type C meeting to discuss future trial - TradingView
Theravance Biopharma (NASDAQ:TBPH): What Could Its Scheduled Update Reveal? - Kalkine Media
FDA says Theravance (TBPH) needs more data on nOH drug trial - Stock Titan
Theravance (TBPH) Q1 2026 Scorecard: EPS Beats Its Estimate in the Current Update; Closing Move: The Stock Records a Flat ReactionForward EPS Estimate - vinanet.vn
Theravance (NASDAQ: TBPH) sets vote on cash buyout with ampreloxetine CVR upside - Stock Titan
Madison Avenue Partners, LP Trims Theravance Biopharma Inc (TBPH) Stake in Portfolio Rebalancing Move - GuruFocus
Theravance Biopharma, Inc. Revenue Breakdown – NASDAQ:TBPH - TradingView
Theravance (TBPH) Update: Rises 0.18% to $16.98 on the Day; Price Setup: Traders Can Monitor the $16.13-$17.83 RangeSupport Level Bounce - vinanet.vn
Theravance Biopharma (TBPH) Edges Higher to $16.97, Trapped Between Key Support and ResistanceFactor Valuation - vinanet.vn
Finanzdaten der Theravance Biopharma Inc-Aktie (TBPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):